2015 ATS conference sleep talks overshadowed by the discussion about ASV negative outcome in heart failure: sleep medicine highlights from the 2015 ATS annual conference in Denver

摘要

This year's ATS conference was for many clinical sleep physicians no business as usual. The public announcement of the not-yet-published results of the 5-year assisted servoventilation (ASV) multicenter trial in patients with heart failure and central apneas (Cheynes Stokes respiration) a few days before the conference made them thinking: what's next? ATS organizers had given Resmed representatives the possibility to speak to a somewhat confused audience at the end of the "High Impact Sleep Science" symposium chaired by Susan Redline and explain what happened. The chair of the Resmed Academy, which is in charge of Resmed trials, research, and educational programs, Holger Woehrle MD, stated that in their multicenter trial regarding the effect of ASV on heart efficiency in heart failure patients, the ASV patients had a more negative outcome than controls without ASV treatment. The hypothesis that ASV would improve ejection fraction and mortality proofed negative.